Current Headlines

  1. Glialogix Receives National Multiple Sclerosis Society Funding For Treatment Development
    10/1/2014

    Glialogix announced that it had signed a research agreement with the non-profit Fast Forward, a part of the National Multiple Sclerosis Society (NMSS), which would fund continued development of GLX1112, a neuroprotective oral therapy with the potential to treat progressive MS. 

  2. Rare Antibodies May Be Key To Future HIV Vaccine
    9/30/2014

    A team of researchers from The Scripps Research Institute (TSRI) reported their findings about a single family of antibodies that could adapt to fight the elusive HIV virus and its different strains. Their discovery may one day provide the key to designing an effective HIV vaccine in the future.

  3. Researchers Identify Potential Treatment For Deadly Kidney Disease
    9/30/2014

    Biochemists at UCLA have uncovered a potential treatment for PH1, a rare and potentially deadly genetic kidney disease in children.

  4. U.K. Researchers On Track To Develop Enzyme-Blocking Cancer, Alzheimer’s “Wonder Drug”
    9/30/2014

    Scientists at the Imperial College London have discovered a molecule with the potential to block the activity of an enzyme that is responsible for the progression of disease. Further investigation and development could yield a revolutionary and potent treatment for serious diseases, such as cancer, Alzheimer’s disease, and diabetes.

  5. Novo Nordisk To Focus On Obesity With New Seattle Research Unit
    9/30/2014

    Novo Nordisk is focusing efforts on obesity treatments and is building a new obesity research unit in Seattle, WA. The company announced the initiative in a press release. The Novo Nordisk Obesity Research Unit will initially employ 10 people, reaching 60 by the end of 2016. The new center will concentrate on basic research and treatments for obesity. Mads Krogsgaard Thomsen, EVP and CSO at Novo Nordisk, said, “Our ambition is to drive scientific progress in the obesity disease area and through this, identify and develop new treatment options for people with obesity.”

  6. Novel Compound Shows Promise In Fighting Multiple Myeloma
    9/29/2014

    Scientists at the Dana-Farber Cancer Institute have shown that a novel compound prevents metastasis of multiple myeloma in mouse models, and it is this discovery that will form the basis of the company’s future plans to progress the compound into human trials.

  7. MIT Team Hacks Anthrax To Deliver Cancer Drugs
    9/29/2014

    A team of chemists from the Massachusetts Institute of Technology (MIT) reported that they have turned to bacillus anthracis bacteria, the culprit behind anthrax infection, in order to deliver cancer drugs more effectively.

  8. FDA Grants Orphan Status To MabVax’s Neuroblastoma Vaccine
    9/29/2014

    Clinical stage oncology drug development firm MabVax Therapeutics announced that it has received the coveted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its vaccine targeting childhood cancer neuroblastoma.

  9. NIH Funds Phase 2 Of ‘Tissue Chip For Drug Screening’ Program
    9/26/2014

    The National Institutes of Health (NIH) announced that it will award funds to support the next phase of the Tissue Chip for Drug Screening program, which will attempt to a build a human-like system to test drugs’ safety and efficacy.

  10. Researchers Develop New Anticancer Peptide Vaccines and Inhibitors
    9/26/2014

    Two new anticancer peptide vaccines and two peptide inhibitors have been developed by researchers at The Ohio State University Comprehensive Cancer Center as part of a larger peptide immunotherapy project.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.